A Study of YM178 in Subjects With Symptoms of Overactive Bladder

NCT01043666 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1126

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder, Overactive

Interventions

DRUG: YM178
DRUG: Placebo
DRUG: tolterodine ER

Sponsor

Astellas Pharma Inc